PTGX Relative Valuation
PTGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTGX is overvalued; if below, it's undervalued.
Historical Valuation
Protagonist Therapeutics Inc (PTGX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -19.90. The fair price of Protagonist Therapeutics Inc (PTGX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：86.07
Fair
63.81
PE
1Y
3Y
5Y
Trailing
Forward
1216.01
EV/EBITDA
Protagonist Therapeutics Inc. (PTGX) has a current EV/EBITDA of 1216.01. The 5-year average EV/EBITDA is 39.98. The thresholds are as follows: Strongly Undervalued below -377.81, Undervalued between -377.81 and -168.92, Fairly Valued between 248.87 and -168.92, Overvalued between 248.87 and 457.77, and Strongly Overvalued above 457.77. The current Forward EV/EBITDA of 1216.01 falls within the Strongly Overvalued range.
-250.64
EV/EBIT
Protagonist Therapeutics Inc. (PTGX) has a current EV/EBIT of -250.64. The 5-year average EV/EBIT is -4.02. The thresholds are as follows: Strongly Undervalued below -160.16, Undervalued between -160.16 and -82.09, Fairly Valued between 74.05 and -82.09, Overvalued between 74.05 and 152.13, and Strongly Overvalued above 152.13. The current Forward EV/EBIT of -250.64 falls within the Strongly Undervalued range.
22.48
PS
Protagonist Therapeutics Inc. (PTGX) has a current PS of 22.48. The 5-year average PS is 40.93. The thresholds are as follows: Strongly Undervalued below -15.00, Undervalued between -15.00 and 12.96, Fairly Valued between 68.90 and 12.96, Overvalued between 68.90 and 96.86, and Strongly Overvalued above 96.86. The current Forward PS of 22.48 falls within the Historic Trend Line -Fairly Valued range.
26.09
P/OCF
Protagonist Therapeutics Inc. (PTGX) has a current P/OCF of 26.09. The 5-year average P/OCF is 23.33. The thresholds are as follows: Strongly Undervalued below -287.17, Undervalued between -287.17 and -131.92, Fairly Valued between 178.58 and -131.92, Overvalued between 178.58 and 333.84, and Strongly Overvalued above 333.84. The current Forward P/OCF of 26.09 falls within the Historic Trend Line -Fairly Valued range.
36.39
P/FCF
Protagonist Therapeutics Inc. (PTGX) has a current P/FCF of 36.39. The 5-year average P/FCF is 32.74. The thresholds are as follows: Strongly Undervalued below -254.59, Undervalued between -254.59 and -110.92, Fairly Valued between 176.40 and -110.92, Overvalued between 176.40 and 320.06, and Strongly Overvalued above 320.06. The current Forward P/FCF of 36.39 falls within the Historic Trend Line -Fairly Valued range.
Protagonist Therapeutics Inc (PTGX) has a current Price-to-Book (P/B) ratio of 8.33. Compared to its 3-year average P/B ratio of 4.47 , the current P/B ratio is approximately 86.24% higher. Relative to its 5-year average P/B ratio of 4.21, the current P/B ratio is about 97.93% higher. Protagonist Therapeutics Inc (PTGX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.64%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.08% , the current FCF yield is about -100.00% lower.
8.45
P/B
Median3y
4.47
Median5y
4.21
1.18
FCF Yield
Median3y
-1.64
Median5y
-6.08
Competitors Valuation Multiple
The average P/S ratio for PTGX's competitors is 0.00, providing a benchmark for relative valuation. Protagonist Therapeutics Inc Corp (PTGX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 0.79%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PTGX increased by 126.24% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 58.32 to 121.26.
The secondary factor is the Margin Expansion, contributed 17.53%to the performance.
Overall, the performance of PTGX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Protagonist Therapeutics Inc (PTGX) currently overvalued or undervalued?
What is Protagonist Therapeutics Inc (PTGX) fair value?
How does PTGX's valuation metrics compare to the industry average?
What is the current P/B ratio for Protagonist Therapeutics Inc (PTGX) as of Dec 05 2025?
What is the current FCF Yield for Protagonist Therapeutics Inc (PTGX) as of Dec 05 2025?
What is the current Forward P/E ratio for Protagonist Therapeutics Inc (PTGX) as of Dec 05 2025?